Shares of Gilead Sciences Inc. GILD slid 4.80% to $97.88 Tuesday, on what proved to be an all-around poor trading session for ...

On April 29, 2025, the U.S. Attorney’s Office for the Southern District of New York (SDNY) announced a $202 million civil False Claims Act ...

Foster City, California-based Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, develops, and ...

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

Gilead Sciences (NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. After ...

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle claims it used speaker ...

After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

As it applies to the development of cell therapies, AstraZeneca’s chief of global operations, Pam Cheng, admits that the ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

Sales of cancer drug Trodelvy fell 5% to $293 million, below analysts' estimates of $362 million, due to pricing and ...

Gilead (GILD) stock and Vertex Pharma (VRTX) stock are said to be relatively immune to Trump administration's tariffs threats ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...